Among his many successes in the biotechnology and life sciences industries, executive and investor Dr. Lindsay Rosenwald counts Cougar Biotechnology, Inc., as a major coup for both business and cancer research.

2.  Among his many successes in the biotechnology
and life sciences industries, executive and investor
Dr. Lindsay Rosenwald counts Cougar
Biotechnology, Inc., as a major coup for both
business and cancer research.
 As the co-founder and earliest financier of Cougar
Biotechnology, Dr. Lindsay Rosenwald provided
the drug development team with the needed
resources to advance its innovative work in
abiraterone acetate, a valuable tool in prostate
cancer treatment that has shown resistance to
other cancers.

3.  Following the acquisition of licensing rights for
abiraterone from the UK pharmaceutical company BTG
plc, Cougar continued the development of the drug
with an eye toward eventual commercialization.
 By the end of its phase 2 trials on abiraterone, Cougar
and all of its drugs currently under development were
purchased by Johnson & Johnson for nearly $1 billion
in 2009.
 Since then, J&J has acquired FDA approval for
Cougar’s flagship drug and markets it as Zytiga in the
United States.